Yarrow Bioscience (YARW) Earnings Date & Reports

Key Takeaways

• Yarrow Bioscience, Inc. (YARW), a clinical-stage biotechnology company, is expected to report its third quarter 2026 results on or about November 17, 2026.
• As a pre-commercial biotech, Yarrow generates minimal revenue, so investors will focus on operating losses, research and development (R&D) spending, and cash runway rather than top-line growth.
• Analyst consensus points to a net loss of roughly $0.32 per share and revenue of about $0.2 million for the quarter, consistent with the company's early-stage profile.
• Attention will center on updates to YB-101, the company's lead anti-TSHR antibody candidate for Graves' disease and thyroid eye disease (TED), now advancing in a Phase 2a/2b clinical trial.
• Recent capital raises, including a $172.5 million underwritten public offering, have bolstered the balance sheet and extended the company's operating runway.
• Wall Street sentiment remains broadly positive, with a Strong Buy consensus rating and 12-month price targets well above recent trading levels.
• For more detail, explore Yarrow's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Looking for automated ideas? Explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

Yarrow Bioscience began trading on Nasdaq under the YARW ticker in July 2026, following a reverse merger with VYNE Therapeutics and a concurrent private financing of roughly $200 million led by RTW Investments. The company is advancing YB-101, a potentially first-in-class humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), designed to address the central mechanism of both Graves' disease and thyroid eye disease. For a clinical-stage biotech, quarterly earnings are less about revenue and more about disciplined cash management and clinical execution. Investors will read the third-quarter report primarily for signals on spending trends, balance-sheet strength, and any operational updates that could de-risk the YB-101 development timeline.

Earnings Expectations

Because Yarrow is pre-revenue in a commercial sense, consensus expectations are modest and focused on losses. Analysts currently model a net loss of approximately $0.32 per share for the third quarter of 2026, alongside revenue of roughly $0.2 million, which primarily reflects collaboration or licensing activity rather than product sales. For context, Yarrow's most recent report — for the second quarter of 2026, released on August 13 — showed a wider-than-expected net loss per share against consensus, underscoring the volatility of early-stage biotech financials as R&D and clinical trial costs ramp up. Investors will be watching whether operating expenses remain in line with guidance and whether management reaffirms its projected cash runway into the Phase 2a data readout, which is currently anticipated in the second half of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors monitoring early-stage names like YARW, it offers a structured way to compare technical setups and momentum across the broader biotech landscape. Explore the AI Screener to build a watchlist tailored to your criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter print has been shaped less by near-term financials and more by the company's clinical narrative and capital position. Since its July 2026 debut, YARW has experienced significant volatility — a common trait among newly public, low-float clinical-stage biotechs — and the stock has traded well below its post-merger highs. Analyst coverage remains constructive, with a Strong Buy consensus rating and price targets that imply substantial upside from current levels, reflecting optimism around YB-101's differentiated mechanism. However, risk factors heading into earnings include the timing and cost of the ongoing Phase 2a/2b trial, potential dilution from future financings, and the possibility of R&D expense growth outpacing street models, which could pressure the stock in the near term.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most consequential catalyst for Yarrow Bioscience is not a single quarter of financial results but the clinical trajectory of YB-101. Management has guided that data from the Phase 2a portion of the trial is expected in the second half of 2027, a milestone that could materially reshape the company's valuation. In the interim, investors should monitor enrollment progress and any safety or biomarker updates that management chooses to share on the earnings call.

On the financial side, cash runway remains a central concern. The company's recent public offerings have meaningfully strengthened its balance sheet, but clinical-stage biotechs typically require multiple financings before reaching pivotal data. Investors will want to confirm that management's stated runway extends comfortably toward, or beyond, the anticipated data readout, reducing near-term dilution risk.

Finally, watch expense discipline. R&D and general and administrative (G&A) spending should be evaluated against guidance, as any unexpected step-up in costs can alter runway assumptions. Competitive developments in the autoimmune thyroid space — including progress by other anti-TSHR antibody programs — may also influence sentiment. Together, these factors make YARW's quarterly updates as much about narrative continuity and execution as about the reported numbers themselves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations